Vaccine Failure

Dr John Campbell is someone who supported the vaccines and someone who the normies watch.  He is coming around…slowly…..to reality:

Vaccine failure in Gibraltar. John Campbell coming around? https://t.co/YsNgVECepd Welcome to the party John.https://t.co/EQgkQJu6zY

— Moses Eleftheria (@EleftheriaMoses) November 26, 2021

Gibraltar, vaccine failure (25 min)

It is “correlated” with a reduction in death?    Really?   All those who were at maximum risk got taken out in the previous wave….that is why.  And you have not even started to see the long-term vaccine injury deaths yet.

Gibraltar Population, 33,691 Has administered at least 94,469 vaccine doses Enough to have fully vaccinated 140.2% of the country’s population. Face masks required in all shops and supermarkets, public transport, in medical centres, indoor funerals, Airport. https://www.worldometers.info/coronav… Europe https://www.who.int/emergencies/disea… World Health Organization Europe remains “in the firm grip” Death toll could top 2.2 million this winter Another 700,000 deaths by March 1 high or extreme stress in intensive care units (ICUs) in 49 out of 53 countries between now and March 1, 2022 Director for WHO Europe, Hans Kluge face a challenging winter ahead vaccine plus Face masks reduce COVID incidence by 53 % Over 160,000 deaths could be prevented (by March 1) if universal mask coverage of 95% Pascal Soriot, the chief executive of AstraZeneca https://www.telegraph.co.uk/news/2021… UK not seeing so many hospitalisations relative to Europe despite a high number of cases. Long term T cell immunity after antibodies wane Looks like, AstraZeneca initially gives higher levels of T-cells France, Germany, Spain, Belgium – restricted AZ to the under 65s UK may have high T cells from natural infection and cross immunity from other coronavirus infections Government source European leaders had all these unfounded concerns about AstraZeneca and its use in older people If you look at the data, you can see us using it early has been incredibly helpful in terms of protecting older and vulnerable people from this disease for longer Dr Peter English People whose immune systems have produced a strong T-cell response but a weaker antibody response might be more likely to be infected in the first place but more likely to be able to fight the infection, and they will be much less likely to develop severe disease It is plausible that this generated an excellent T-cell response, which means that while people can still be infected and infectious, they are unlikely to be seriously unwell Prof Matthew Snape, Oxford University The best T-cell responses seem to come if you give a first dose of the AstraZeneca vaccine followed by Pfizer Prof Dame Sarah Gilbert Third jabs may be unnecessary UK https://coronavirus.data.gov.uk US https://www.cdc.gov/coronavirus/2019-… Centers for Disease Control and Prevention Director Rochelle Walensky Seven-day average Cases up 18% Hospital admissions up 6% 135 million people eligible for boosters Heading into the winter months, when respiratory viruses are more likely to spread, and with plans for increased holiday season travel and gatherings, boosting people’s overall protection against covid-19 disease and death was important to do now In the fully vaccinated https://www.cdc.gov/coronavirus/2019-… Infections happen in only a small proportion of people who are fully vaccinated, even with the Delta variant. When these infections occur among vaccinated people, they tend to be mild If you are fully vaccinated and become infected with the Delta variant, you can spread the virus to others Dr Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases https://www.businessinsider.com/fauci… Next spring Pfizer trial ongoing 6 months to 5 years Moderna and Johnson & Johnson, have pediatric vaccine trials planned Emergency use authorization to the Food and Drug Administration Canada https://www.canada.ca/en/health-canad… Health Canada Pfizer-BioNTech Comirnaty, in children 5 to 11 years (12 to 15s, May 5, 2021) the Department has determined that the benefits of this vaccine for children between 5 and 11 years of age outweigh the risks Two-dose regimen, 10 micrograms Three weeks apart Immune response in children 5 to 11 years, comparable to 16 to 25 The vaccine was 90.7% effective at preventing COVID-19 in children 5 to 11 years of age and no serious side effects were identified Ongoing studies and real-world data to ensure that the benefits of the vaccine continue to outweigh any risks, as well as to detect any potential new safety signals in any age group